Jiankun Lyu

Education Background                                                                                   
 
Ph.D. Candidate (Sep. 2013 - Jan. 2019)
School of Pharmacy, East China University of Science and Technology, Shanghai, China
Major: Pharmaceutical Science (GPA: 3.5/4.0)
 
Bachelor of Engineering (Sep. 2009 – Jul. 2013, Date Obtained: July.2013)
School of Pharmacy, East China University of Science and Technology, Shanghai, China
Major: Pharmaceutical Engineering (GPA: 3.4/4.0, Major GPA: 3.7/4.0)
Thesis Title: Discovery of inhibitors against FMS-like Tyrosine kinase 3 (FLT3) through its refined homology model
 
Research Experience                                                                                   
 
1. Identification of Antiproliferative and Apoptosis-inducing Activities of Novel Naphthalimide–Cyclam Conjugates through Dual Topoisomerase (topo) I/II Inhibition; 
2. Rational Design and Development of FLT3 Inhibitors;
3. Rational Design and Development of EGFR Irreversible Inhibitors;
4. Development of Computational Methods for Investigating Drug-Target Binding Thermodynamics and Kinetics.
 

Publications                                                                                                   

Shaoying Tan†, Deheng Sun†, Jiankun Lyu†, Xiao Sun, Fangshu Wu, Qiang Li, Yiqi Yang, Jianxu Liu, Xin Wang, Zhuo Chen*, Honglin Li*, Xuhong Qian, Yufang Xu*. Antiproliferative and apoptosis-inducing activities of novel naphthalimide–cyclam conjugates through dual topoisomerase (topo) I/II inhibition. Bioorgan. Med. Chem. 2015, 23(17), 5672-5680, doi:10.1016/j.bmc.2015.07.011

Deheng Sun, Yu Yang, Jiankun Lyu, Wei Zhou, Wenlin Song, Zhenjiang Zhao, Zhuo Chen*, Yufang Xu*, and Honglin Li*. Discovery and rational design of pteridin-7(8H)-one-based inhibitors targeting FMS-like tyrosine kinase 3 (FLT3) and its mutants. J. Med. Chem. 2016, 59(13): 6187-6200, doi:10.1021/acs.jmedchem.6b00374

Yongjia Hao, Jiankun Lyu, Rong Qu, Deheng Sun, Zhenjiang Zhao, Zhuo Chen, Jian Ding, Hua Xie*, Yufang Xu*, Honglin Li*. Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors. Sci. Rep., 2017, 7 : 3830.

Yongjia Hao, Jiankun Lyu, Rong Qu, Yi Tong, Deheng Sun, Fang Feng, Linjiang Tong, Tingyuan Yang, Zhenjiang Zhao, Lili Zhu, Jian Ding, Yufang Xu*, Hua Xie*, Honglin Li*. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5-d]pyrimidine-2,4(1H, 3H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. J. Med. Chem., 2018, 61 (13), 5609-5622.

Qiao Li, Lina Quan, Jiankun Lyu, Zenghui He, Xia Wang, Jiajia Meng, Zhenjiang Zhao, Lili Zhu*, Xiaofeng Liu*, Honglin Li*. Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. Oncotarget, 2016, 7 : 64967-64976.

Yi Tong, Qian Jiao, Yuanru Liu, Jiankun Lyu, and Rui Wang* and Lili Zhu*. Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats. Front. Pharmacol., 2018, 9 : 1032.

 

 

User Login


Contact us


Honglin Li's Lab
Shanghai Key Laboratory of New Drug Design
School of Pharmacy
East China University of Sci. & Tech.
Room 527, Building 18, 130 Meilong Road,
Shanghai, 200237, P. R. China
Tel: (86) 21 6425 0213
Prof. Honglin Li
hlli@ecust.edu.cn

Copyright © 2019 Prof. HongLin Li's Group, School of Pharmacy, East China University of Science & Technology · All Right Reserved.
沪ICP备19004698号-1 |  沪公网安备31011302004713号